Crosspoint Financial News Today

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among brokerages […]

A Global X report shows assets under management (AUM) for thematic ETFs peaked at nearly US$150-billion at the end of 2021, but recently the AUM has declined by about $70-billion

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Equities researchers at HC Wainwright increased their Q3 2023 EPS estimates for Allogene Therapeutics in a report issued on Monday, August 7th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.48) per share for the quarter, up from their prior estimate […]

Decisions on when to collect CPP benefits and to convert RRSPs can have a profound effect on clients' retirement income